Table 1.
Patient and disease characteristics
| Baseline characteristic | Total (N = 45) |
|---|---|
| Median age, year (range) | 67 (52–86) |
| Race, n (%) | |
| White | 42 (93) |
| Black or African American | 3 (7) |
| Median weight, kg (range) | 80 (50–135) |
| Median time from initial diagnosis, mo (range) | 68.2 (3.9–280.3) |
| Extent of disease, n (%) | |
| Bone | 40 (91) |
| Soft tissue or node | 14 (32) |
| Liver | 2 (4) |
| Lung | 1 (2) |
| Other | 3 (7) |
| None | 1 (2) |
| ECOG PS, n (%) | |
| 0 | 27 (60) |
| 1 | 18 (40) |
| Median testosterone, nM (range) | 0.85 (0.07–1.63) |
| Prior therapy, n (%) | 45 (100) |
| Bicalutamide | 40 (89) |
| Abiraterone acetate | 19 (42) |
| Docetaxel | 17 (38) |
| Cabazitaxel | 11 (24) |
ECOG PS Eastern Cooperative Oncology Group performance status